Every one of those 1 sits in a single category, medical-devices. Charles Schwab is most often covered alongside Douglas J. Swirsky, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 3.3 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Charles Schwab
Every one of those 1 sits in a single category, medical-devices. Charles Schwab is most often covered alongside Douglas J. Swirsky, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 3.3 across the same-window beat baseline. The 7 average consequence score is above the beat benchmark of 6.6 in the same window. We currently track 1 Healthcare story that mention Charles Schwab, all published on March 25, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Charles Schwab. Shared-story counts are live from our verified record — not editorial picks.
MaxCyte reported a 15% revenue decline for 2025, driven by the loss of six clinical programs and reduced spending from its largest customer. Despite these headwinds, the company expanded its installed base to 857 units and significantly improved gross margins through aggressive cost-cutting measures.